Additionally, Cazzamalli et al. reported interesting preclinical data showing that L19-IL-2, in combination with a small-molecule drug conjugate selectively targeting cancer cells expressing carbonic anhydrase IX, exhibited high specificity and efficacy [116]. Here, IL2 is linked to cancer.